Analysis of camrelizumab in neoadjuvant chemotherapy for esophageal cancer: A retrospective cohort study

Li,Jianjun; Chen,Bo; Zheng,Jing

doi:10.3892/ol.2025.15195

Analysis of camrelizumab in neoadjuvant chemotherapy for esophageal cancer: A retrospective cohort study

Authors:
- Jianjun Li
- Bo Chen
- Jing Zheng
View Affiliations

Affiliations: Department of Cardiothoracic Surgery, Banan Hospital Affiliated to Chongqing Medical University, Chongqing 401320, P.R. China, Department of Operations Management Office, Banan Hospital Affiliated to Chongqing Medical University, Chongqing 401320, P.R. China
Published online on: July 17, 2025 https://doi.org/10.3892/ol.2025.15195
Article Number: 449
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Neoadjuvant therapy has the potential to enhance the prognosis of esophageal squamous cell carcinoma (ESCC). Camrelizumab, a domestically developed programmed cell death protein 1 inhibitor in China, offers a convenient treatment option for Chinese patients with ESCC. The NIC‑ESCC2019 trial has demonstrated that the combination of camrelizumab and neoadjuvant chemotherapy has favorable efficacy and tolerable toxicity for resectable ESCC. However, limited real‑world comparative data exist regarding its efficacy and safety in Chinese patients with ESCC, necessitating further investigation. The present study aimed to evaluate the clinical efficacy and safety of camrelizumab in combination with paclitaxel and cisplatin for the neoadjuvant treatment of locally advanced ESCC. A retrospective analysis of clinical and pathological data was performed on 70 patients with locally advanced esophageal cancer who underwent neoadjuvant chemotherapy or chemo‑immunotherapy followed by radical esophagectomy at Banan Hospital Affiliated to Chongqing Medical University from February 2021 to August 2023. Patients were divided into two groups based on treatment received: A control group (35 patients; neoadjuvant chemotherapy, paclitaxel + cisplatin) and an observation group (35 patients; camrelizumab + paclitaxel + cisplatin). Short‑term efficacy, treatment‑related adverse reactions (graded using Common Terminology Criteria for Adverse Events v5.0), and postoperative pathological complete remission (pCR) rate were compared. Baseline characteristics were comparable. The observation group had a significantly higher pCR rate compared with the control group (40.0 vs. 8.57%; P=0.002). All patients in the observation group achieved R0 resection, versus 32 (91.4%) in the control group. No grade ≥4 adverse events (AEs) occurred. Reactive cutaneous capillary endothelial proliferation was observed in 45.7% of the observation group (vs. 0% in controls; P<0.05), with no significant differences in other AEs (P>0.05). Neoadjuvant camrelizumab combined with paclitaxel and cisplatin may notably enhance pCR rates in locally advanced ESCC, with a manageable safety profile. The present findings suggest potential clinical benefit, but confirmation through prospective, randomized trials is essential to validate the regimen's efficacy and long‑term outcomes.

View Figures

View References

1	Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.PubMed/NCBI
2	Zheng R, Zhang S, Zeng H, Wang S, Sun K, Chen R, Li L, Wei W and He J: Cancer incidence and mortality in China, 2016. J Natl Cancer Cent. 2:1–9. 2022.PubMed/NCBI
3	Arnold M, Soerjomataram I, Ferlay J and Forman D: Global incidence of oesophageal cancer by histological subtype in 2012. Gut. 64:381–387. 2015. View Article : Google Scholar : PubMed/NCBI
4	Baba Y, Yoshida N, Kinoshita K, Iwatsuki M, Yamashita YI, Chikamoto A, Watanabe M and Baba H: Clinical and prognostic features of patients with esophageal cancer and multiple primary cancers: A retrospective single-institution study. Ann Surg. 267:478–483. 2018. View Article : Google Scholar : PubMed/NCBI
5	Huang TX and Fu L: The immune landscape of esophageal cancer. Cancer Commun (Lond). 39:792019. View Article : Google Scholar : PubMed/NCBI
6	Sihag S, Ku GY, Tan KS, Nussenzweig S, Wu A, Janjigian YY, Jones DR and Molena D: Safety and feasibility of esophagectomy following combined immunotherapy and chemoradiotherapy for esophageal cancer. J Thorac Cardiovasc Surg. 161:836–843.e1. 2021. View Article : Google Scholar : PubMed/NCBI
7	Kelly RJ: Immunotherapy for esophageal and gastric cancer. Am Soc Clin Oncol Educ Book. 37:292–300. 2017. View Article : Google Scholar : PubMed/NCBI
8	Qiao Y, Zhao C, Li X, Zhao J, Huang Q, Ding Z, Zhang Y, Jiao J, Zhang G and Zhao S: Efficacy and safety of camrelizumab in combination with neoadjuvant chemotherapy for ESCC and its impact on esophagectomy. Front Immunol. 13:9532292022. View Article : Google Scholar : PubMed/NCBI
9	Yin GQ, Li ZL and Li D: The safety and efficacy of neoadjuvant camrelizumab plus chemotherapy in patients with locally advanced esophageal squamous cell carcinoma: A retrospective study. Cancer Manag Res. 14:2133–2141. 2022. View Article : Google Scholar : PubMed/NCBI
10	Zeng H, Chen W, Zheng R, Zhang S, Ji JS, Zou X, Xia C, Sun K, Yang Z, Li H, et al: Changing cancer survival in China during 2003-15: A pooled analysis of 17 population-based cancer registries. Lancet Glob Health. 6:e555–e567. 2018. View Article : Google Scholar : PubMed/NCBI
11	Short MW, Burgers KG and Fry VT: Esophageal cancer. Am Fam Physician. 95:22–28. 2017.PubMed/NCBI
12	Kitagawa Y, Uno T, Oyama T, Kato K, Kato H, Kawakubo H, Kawamura O, Kusano M, Kuwano H, Takeuchi H, et al: Esophageal cancer practice guidelines 2017 edited by the Japan esophageal society: Part 1. Esophagus. 16:1–24. 2019. View Article : Google Scholar : PubMed/NCBI
13	Ajani JA, D'Amico TA, Bentrem DJ, Chao J, Corvera C, Das P, Denlinger CS, Enzinger PC, Fanta P, Farjah F, et al: Esophageal and esophagogastric junction cancers, version 2.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 17:855–883. 2019. View Article : Google Scholar : PubMed/NCBI
14	van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, Richel DJ, Nieuwenhuijzen GA, Hospers GA, Bonenkamp JJ, et al: Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 366:2074–2084. 2012. View Article : Google Scholar : PubMed/NCBI
15	Yang H, Liu H, Chen Y, Zhu C, Fang W, Yu Z, Mao W, Xiang J, Han Y, Chen Z, et al: Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus (NEOCRTEC5010): A phase III multicenter, randomized, open-label clinical trial. J Clin Oncol. 36:2796–2803. 2018. View Article : Google Scholar : PubMed/NCBI
16	Topalian SL, Drake CG and Pardoll DM: Immune checkpoint blockade: A common denominator approach to cancer therapy. Cancer Cell. 27:450–461. 2015. View Article : Google Scholar : PubMed/NCBI
17	Gotwals P, Cameron S, Cipolletta D, Cremasco V, Crystal A, Hewes B, Mueller B, Quaratino S, Sabatos-Peyton C, Petruzzelli L, et al: Prospects for combining targeted and conventional cancer therapy with immunotherapy. Nat Rev Cancer. 17:286–301. 2017. View Article : Google Scholar : PubMed/NCBI
18	Zheng Y, Wang Z, Yan C, Yan M, Hou Z, Zheng R, Zhu Z and Li C: Protocol for a randomized controlled trial of perioperative S-1 plus oxaliplatin combined with apatinib and camrelizumab in patients with resectable, locally advanced gastric or gastroesophageal junction adenocarcinoma. Ann Transl Med. 8:16842020. View Article : Google Scholar : PubMed/NCBI
19	Liu Y, Wang C, Li X, Dong L, Yang Q, Chen M, Shi F, Brock M, Liu M, Mei Q, et al: Improved clinical outcome in a randomized phase II study of anti-PD-1 camrelizumab plus decitabine in relapsed/refractory Hodgkin lymphoma. J Immunother Cancer. 9:e0023472021. View Article : Google Scholar : PubMed/NCBI
20	Zhang B, Qi L, Wang X, Xu J, Liu Y, Mu L, Wang X, Bai L and Huang J: Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first-line treatment of advanced esophageal squamous cell carcinoma. Cancer Commun (Lond). 40:711–720. 2020. View Article : Google Scholar : PubMed/NCBI
21	Zhang W, Yan C, Gao X, Li X, Cao F, Zhao G, Zhao J, Er P, Zhang T, Chen X, et al: Safety and feasibility of radiotherapy plus camrelizumab for locally advanced esophageal squamous cell carcinoma. Oncologist. 26:e1110–e1124. 2021. View Article : Google Scholar : PubMed/NCBI
22	Chen Z, Lu X and Koral K: The clinical application of camrelizumab on advanced hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol. 14:1017–1024. 2020. View Article : Google Scholar : PubMed/NCBI
23	Hou X, Shi X and Luo J: Efficacy and safety of camrelizumab (a PD-1 inhibitor) combined with chemotherapy as a neoadjuvant regimen in patients with locally advanced non-small cell lung cancer. Oncol Lett. 24:2152022. View Article : Google Scholar : PubMed/NCBI
24	Masterson L, Howard J, Gonzalez-Cruz J, Jackson C, Barnett C, Overton L, Liu H, Ladwa R, Simpson F, McGrath M, et al: Immune checkpoint inhibitors in advanced nasopharyngeal carcinoma: Beyond an era of chemoradiation? Int J Cancer. 146:2305–2314. 2020. View Article : Google Scholar : PubMed/NCBI
25	Zhou RQ, Luo J, Li LJ, Du M and Wu QC: Neoadjuvant camrelizumab plus chemotherapy in locally advanced oesophageal squamous cell carcinoma: A retrospective cohort study. BMC Surg. 23:1142023. View Article : Google Scholar : PubMed/NCBI
26	Liu J, Yang Y, Liu Z, Fu X, Cai X, Li H, Zhu L, Shen Y, Zhang H, Sun Y, et al: Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma. J Immunother Cancer. 10:e0042912022. View Article : Google Scholar : PubMed/NCBI
27	Yang W, Xing X, Yeung SJ, Wang S, Chen W, Bao Y, Wang F, Feng S, Peng F, Wang X, et al: Neoadjuvant programmed cell death 1 blockade combined with chemotherapy for resectable esophageal squamous cell carcinoma. J Immunother Cancer. 10:e0034972022. View Article : Google Scholar : PubMed/NCBI
28	Yang P, Zhou X, Yang X, Wang Y, Sun T, Feng S and Ma X: Neoadjuvant camrelizumab plus chemotherapy in treating locally advanced esophageal squamous cell carcinoma patients: A pilot study. World J Surg Oncol. 19:3332021. View Article : Google Scholar : PubMed/NCBI
29	Liu J, Li J, Lin W, Shao D, Depypere L, Zhang Z, Li Z, Cui F, Du Z, Zeng Y, et al: Neoadjuvant camrelizumab plus chemotherapy for resectable, locally advanced esophageal squamous cell carcinoma (NIC-ESCC2019): A multicenter, phase 2 study. Int J Cancer. 151:128–137. 2022. View Article : Google Scholar : PubMed/NCBI
30	Qin J, Xue L, Hao A, Guo X, Jiang T, Ni Y, Liu S, Chen Y, Jiang H, Zhang C, et al: Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: The randomized phase 3 ESCORT-NEO/NCCES01 trial. Nat Med. 30:2549–2557. 2024. View Article : Google Scholar : PubMed/NCBI
31	Lavaud P, Bortolot M, Zullo L, O'Reilly D, Naidoo J, Mountzios G, Mercier O, Hendriks LEL and Remon J: Early-Stage non-small cell lung cancer: New challenges with immune checkpoint blockers and targeted therapies. Cancers (Basel). 16:27792024. View Article : Google Scholar : PubMed/NCBI
32	Lei J, Zhao J, Gong L, Ni Y, Zhou Y, Tian F, Liu H, Gu Z, Huang L, Lu Q, et al: Neoadjuvant camrelizumab plus platinum-based chemotherapy vs chemotherapy alone for Chinese patients with resectable stage IIIA or IIIB (T3N2) non-small cell lung cancer: The TD-FOREKNOW randomized clinical trial. JAMA Oncol. 9:1348–1355. 2023. View Article : Google Scholar : PubMed/NCBI
33	Shao M, Yao J, Wang Y, Zhao L, Li B, Li L, Wu Z, Chen Z, Fan J and Qiu F: Two vs three cycles of neoadjuvant sintilimab plus chemotherapy for resectable non-small-cell lung cancer: neoSCORE trial. Signal Transduct Target Ther. 8:1462023. View Article : Google Scholar : PubMed/NCBI
34	Sun C, Liu Y, Zhang P, Wang X, Xu Y, Lin X, Ma X, Guo Y, Qiu S, Shao G, et al: Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: A single-arm, phase 2 trial. J Cancer Res Clin Oncol. 149:819–831. 2023. View Article : Google Scholar : PubMed/NCBI
35	Qiu Y, Su G, Zhang L, Fan H, Zhao H, Wang C, Liu L, Chen B, Li X and Li S: Association between reactive cutaneous capillary endothelial proliferation and the efficacy of camrelizumab in esophageal cancer: A retrospective cohort study. J Thorac Dis. 17:2453–2472. 2025. View Article : Google Scholar : PubMed/NCBI
36	Song G, Zhang FF and Cheng HD: Thalidomide for prevention of camrelizumab-induced reactive cutaneous capillary endothelial proliferation. Australas J Dermatol. 63:217–221. 2022. View Article : Google Scholar : PubMed/NCBI
37	Li Q, Cao M, Yuan G, Cheng X, Zang M, Chen M, Hu X, Huang J, Li R, Guo Y, et al: Lenvatinib Plus Camrelizumab vs. Lenvatinib monotherapy as first-line treatment for unresectable hepatocellular carcinoma: A multicenter retrospective cohort study. Front Oncol. 12:8097092022. View Article : Google Scholar : PubMed/NCBI